# Market Mayhem: Reverse-Split Roulette Unleashed!

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-09-10T14:02:03.092Z
Source: https://newsyai.com/edition/e1317bbd-b50a-490b-9bb0-1081b856a307
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

**Market Mayhem: Reverse-Split Roulette 21.0 – Finance Trusts, Lion Brokers & Pulmonary Stiffies (September 10, 2026 Edition!)**

Futures mixed (Dow flatter than a post-split microcap after a raise, Nasdaq still humping the AI/chip wave like a degenerate quant on bonus day, crude oil grinding its usual volatile nut). MVLS drama paused again, but the microcap reverse-split parade keeps marching—yesterday’s defense pivots, GPU leasers, and EV/hydrogen dreamers? Old news. Fresh meat today: three compliance desperados with actual narrative juice—mortgage finance trusts, Asian brokerage plays, and a clinical-stage biotech swinging for the fences with an 80-for-1 hammer. Bulls scream “shrunken float + any pop = rocket”; bears smell serial dilution, cash bonfires, and delisting ghosts.[[1]](https://www.tradingcalendar.com/stock-splits)

### 1) LFT (Lument Finance Trust Inc.): “1-for-10 Mortgage Trust Stiffy vs. REIT Compliance Boner & Dilution Hangover”

**Why it’s loud**  
1-for-10 reverse split effective September 10 for NYSE compliance. Mortgage/finance trust play in a rate-volatile world, post-split float compression, but history of these vehicles screaming for capital.[[1]](https://www.tradingcalendar.com/stock-splits)

**Bull case (compliance rocket + rate boner)**  
10x ratio + “mortgage tailwinds in a Fed-pivoting world” = quick rip on the shrunken float. Ride any rate-cut hype, portfolio update, or sector rebound, degens—tiny float + real housing needs could spark a degen squeeze!

**Bear case (REIT limp dick & dilution tsunami)**  
Rate-sensitive cash flows + compliance desperation screams execution hell; serial raises and microcap volatility = sub-penny graveyard after any pop. Short the fade before the next offering!

**My take, first principles (real mortgage signal vs. listing cancer)**  
Mortgage finance demand is real and rate-sensitive (housing ain’t going away), but repeated splits, leverage risks, and microcap history point to short-term pop on compliance/news rather than durable fundamentals. Narrative lottery with moonshot odds but graveyard probability. Scalp the spunk? **$0.25–2.50** range, **$0.80C** rate/news pump—**P$0.25** dilution fade.

### 2) LGHL (Lion Group Holding Ltd.): “1-for-20 Brokerage Stiffy vs. Asian Finance Dreams & Compliance Limbo”

**Why it’s loud**  
1-for-20 reverse split effective September 10 for Nasdaq bid-price compliance. Financial services/brokerage play with Asia exposure, recent hype around holdings or deals, but chronic compliance fights.[[2]](https://www.stocktitan.net/news/stock-splits.html)

**Bull case (compliance rocket + finance boner)**  
20x ratio + “Asian market tailwinds in booming finance/liquidity plays” = quick rip on the shrunken float. Ride any deal flow, regulatory win, or sector hype wave, degens—tech or expansion validation = explosive moves. Tiny float + real demand could fuel a squeeze!

**Bear case (cash-burn limp dick & dilution tsunami)**  
Pre-revenue-ish burn or execution risks + compliance desperation screams dilution hell; competition, geopolitical noise, and microcap volatility = sub-penny graveyard after any hype pop. Short the fade before the next raise!

**My take, first principles (real finance signal vs. listing cancer)**  
Brokerage/liquidity services in growth markets are legitimate, but repeated splits, cash pressures, and early-stage/microcap risks point to short-term pop on news rather than fundamentals. Narrative lottery with moonshot odds but graveyard probability. Scalp the spunk? **$0.20–2.20** range, **$0.75C** deal/hype pump—**P$0.20** dilution fade.

### 3) GOSS (Gossamer Bio Inc.): “1-for-80 Biotech Stiffy vs. Pulmonary Pipeline Dreams & Massive Split Hangover”

**Why it’s loud**  
1-for-80 reverse split effective September 11 (announced September 9/10) for Nasdaq compliance. Clinical-stage biopharma focused on seralutinib for pulmonary arterial hypertension and related conditions—big ratio screams desperation but pipeline has actual clinical legs.[[3]](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000091/0001728117-26-000091.txt)

**Bull case (compliance rocket + pipeline boner)**  
80x ratio + “unmet pulmonary needs in exploding respiratory markets” = insane rip on the shrunken float. Ride any trial data, partnership, or sector hype wave, degens—real unmet medical needs + tiny float could spark a degen squeeze!

**Bear case (biotech limp dick & dilution tsunami)**  
History of clinical risks + massive compliance split screams execution hell; cash burn, trial misses, and microcap volatility = sub-penny graveyard after any pop. Short the fade before the next raise or data miss!

**My take, first principles (real medical signal vs. listing cancer)**  
Pulmonary hypertension treatments address real, growing unmet needs (aging populations and lung disease ain’t fake), but extreme split ratio, cash pressures, and biotech execution risks point to short-term pop on news/data rather than durable fundamentals. Narrative lottery with moonshot odds but graveyard probability. Scalp the spunk? **$0.10–1.80** range, **$0.60C** data/partnership pump—**P$0.10** dilution fade.

**Tape-Side Tactics (LFT Mortgage Gambles, LGHL Brokerage Pumpers & GOSS Pulmonary Moonshots – September 10 Edition)**  
- **LFT**: **$0.25–2.50** stiffy; **$0.80C** rate/news pump, **P$0.25** dilution fade.  
- **LGHL**: **$0.20–2.20** stiffy; **$0.75C** deal/hype pump, **P$0.20** dilution fade.  
- **GOSS**: **$0.10–1.80** stiffy; **$0.60C** data/partnership pump, **P$0.10** dilution fade.  

MVLS pressure paused but the reverse-split addiction still tightening the noose amid AI hype and micro-madness. Balls-deep DYOR, NFA, degens—duck the dilutions!

**Sources** (for tracking every claim above):  
- Reverse splits & calendars: Trading Calendar, Stock Titan, TipRanks, SEC filings (Sep 2026 data).[[1]](https://www.tradingcalendar.com/stock-splits)[[4]](https://stockanalysis.com/actions/splits/2026/)  
- Company context & filings: SEC/GlobeNewswire/PR Newswire via recent reports.  
- Broader microcap/premarket context & volatility: Yahoo Finance, company IR pages.
